ID: ALA3245411

Max Phase: Preclinical

Molecular Formula: C22H30N4O2

Molecular Weight: 382.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  N=C(N)c1ccc(OCCCCCCCCOc2ccc(C(=N)N)cc2)cc1

Standard InChI:  InChI=1S/C22H30N4O2/c23-21(24)17-7-11-19(12-8-17)27-15-5-3-1-2-4-6-16-28-20-13-9-18(10-14-20)22(25)26/h7-14H,1-6,15-16H2,(H3,23,24)(H3,25,26)

Standard InChI Key:  BCLQWSHAVPTCAD-UHFFFAOYSA-N

Associated Targets(non-human)

Acrosin 53 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 382.51Molecular Weight (Monoisotopic): 382.2369AlogP: 4.05#Rotatable Bonds: 13
Polar Surface Area: 118.20Molecular Species: BASEHBA: 4HBD: 4
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 6#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 12.13CX LogP: 3.66CX LogD: -1.17
Aromatic Rings: 2Heavy Atoms: 28QED Weighted: 0.24Np Likeness Score: -0.13

References

1. Parrish RF, Straus JW, Paulson JD, Polakoski KL, Tidwell RR, Geratz JD, Stevens FM..  (1978)  Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.,  21  (11): [PMID:722718] [10.1021/jm00209a008]
2. Cavalier MC, Ansari MI, Pierce AD, Wilder PT, McKnight LE, Raman EP, Neau DB, Bezawada P, Alasady MJ, Charpentier TH, Varney KM, Toth EA, MacKerell AD, Coop A, Weber DJ..  (2016)  Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations.,  59  (2): [PMID:26727270] [10.1021/acs.jmedchem.5b01369]

Source